Diligence memo · auto-generated · as of July 3, 2026
OrPro Therapeutics, Inc.
OrPro Therapeutics, Inc. looks over-valued against its niche peers and is dormant on financing cadence.
Businessfiled
OrPro Therapeutics, Inc. operates in Biotechnology, based in SAN DIEGO.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
OrPro Therapeutics, Inc. has raised $3.7M in disclosed capital across 2 recorded rounds, aggregated from public filings. Its latest round is modeled as Seed (a $1.0M–$4.0M round).
Largest single filing: $2.3M on 2013-12-11.
Most recent recorded round closed around 2013-12-11.
Valuation (modeled)modeled
Provath models OrPro Therapeutics, Inc. at approximately $104M (range $1.7M–$815M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Over-valued. Modeled value is 1.55× the median modeled value of Seed Biotechnology companies in 2013–2015 (122 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Last raise 12.6 yr ago; this sector typically re-raises about every 14 months.
Silent for over 3× the sector's normal cadence.
The last round stepped up 1.8× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 38% of Biotechnology peers (4293 compared).
Modeled value ranks above 59% of those peers.
Closest niche peers: Harpoon Medical, Inc., Admittance Technologies, Inc., Bell Biosystems, Inc., Nexstim Plc, Iontera, Inc..
Peoplefiled
5 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
Modeled above niche peers — valuation risk on entry.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.